CSPC Wins China Approval for Long-Acting Schizophrenia Injection

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group has received marketing approval in mainland China for its independently developed Paliperidone Palmitate Injection, a second-generation long-acting antipsychotic indicated for both acute and maintenance treatment of schizophrenia. Available in multiple strengths, the once-monthly injection is designed to deliver rapid onset without supplemental oral medication, improving adherence and reducing relapse and rehospitalisation rates for patients with poor treatment compliance.

The product has been recommended in leading domestic and international clinical guidelines, including the 2025 Chinese Guidelines for the Prevention and Treatment of Schizophrenia, underscoring its clinical and pharmacoeconomic value. This approval expands CSPC’s psychiatric and neurological portfolio and strengthens its strategic position in the central nervous system drug market, as the company signals ongoing investment in high-value therapies to broaden treatment options for patients.

The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.